ISRCTN04417063已完成未知
Magnesium sulphate for treatment of severe acute asthma
Sheffield Teaching Hospitals NHS Trust (UK)0 个研究点目标入组 1,200 人开始时间: 2007年2月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 30/04/2008:
- •We will recruit adults (aged greater than 16 years) admitted to the Emergency Department with acute severe asthma as defined by the British Thoracic Society (BTS) and Scottish Intercollegiate Guideline Network (SIGN) guidelines, i.e. acute asthma with either peak expiratory flow rate (PEFR) less than 50% of best or predicted, respiratory rate greater than 25/min, heart rate greater than 110/min, or inability to complete sentences in one breath.
- •Eligible patients will be identified by medical staff and informed consent sought from the patient. Oral consent can be obtained initially, and written consent will be obtained before departure from the emergency department.
- •Consented participants will be randomised by telephone or internet using a system developed for the Sheffield Clinical Trials Research Unit (CTRU). A simple randomisation sequence will be used to allocate participants to numbered treatment packs kept in the emergency department. Each treatment pack will contain an intravenous infusion and a nebuliser solution, either of which could be active treatment or placebo. Participants, hospital staff and research staff will all be blind to allocated treatment.
- •Clinical staff will record baseline data, details of co-interventions and outcome data up to two hours after presentation. Further data will be collected at one month after recruitment by research nurses using routine data sources and by patient self-completion questionnaire.
- •Previous inclusion criteria:
- •We will recruit adults (age>16) admitted to the emergency department with acute severe asthma as defined by the British Thoracic Society (BTS) and Scottish Intercollegiate Guideline Network (SIGN) guidelines, i.e. acute asthma with either Peak Expiratory Flow Rate (PEFR) < 50% of best or predicted, respiratory rate > 25/min, heart rate > 110/min, or inability to complete sentences in one breath.
- •Eligible patients will be identified by medical staff and written, informed consent sought from either the patient, a personal legal representative or a professional legal representative (as outlined in Medicine for Human Use (Clinical Trials) Regulations 2004).
- •Consented participants will be randomised by telephone to the Sheffield Clinical Trials Support Unit (CTSU). A simple randomisation sequence will be used to allocate participants to numbered treatment packs kept in the emergency department. The CTSU will only reveal the allocated pack number after patient details have been recorded and the patient irreversibly entered into the trial. Each treatment pack will contain an intravenous infusion and a nebuliser solution, either of which could be active treatment or placebo. Participants, hospital staff and research staff will all be blind to allocated treatment.
- •Clinical staff will record baseline data, details of co-interventions and outcome data up to two hours after presentation. Further data will be collected at one month after recruitment by research nurses using routine data sources and by patient self-completion questionnaire.
排除标准
- •Current exclusion criteria as of 30/04/2008:
- •1. Patients with life threatening features (oxygen saturation less than 92%, silent chest, cyanosis, poor respiratory effort, bradycardia, arrhythmia, hypotension, exhaustion, coma or confusion)
- •2. Patients who are unable to provide oral or written informed consent
- •3. Patients with a contra-indication to either nebulised or intravenous magnesium sulphate: pregnancy, hepatic or renal failure, heart block or known hypermagnesaemia
- •4. Previous participants in the 3Mg Trial
- •Added 21/03/2011:
- •5. Patients who have received IV or nebulised magnesium sulphate in the previous 24 hours prior to admission to the emergency department.
- •Previous exclusion criteria:
- •1. Patients with life threatening features (oxygen saturation < 92%, silent chest, cyanosis, poor respiratory effort, bradycardia, arrhythmia, hypotension, exhaustion, coma or confusion)
- •2. Patients who are unable to provide written consent and for whom no personal or professional legal representative can be identified to act on their behalf
- •3. Patients with a contraindication to either nebulised or intravenous magnesium sulphate: pregnancy, hepatic or renal failure, heart block or known hypermagnesaemia
- •4. Previous participants in the 3Mg Trial
研究者
相似试验
已完成
不适用
Efficacy of magnesium sulfate in treatment of acute renal colicacute renal colic.N20,N21,N22,N23IRCT2016020223552N6Vice Chancellor for research of Arak University of Medical Sciences100
尚未招募
3 期
Magnesium Sulphate as Adjuvant in Acute Organophosphorus PoisoningCTRI/2024/02/063307JLN Medical College and Hospital
进行中（未招募）
3 期
Magnesium sulfate as an adjunct to cooling of babies who do not cry at birth.CTRI/2018/06/014594JIPMER Puducherry
已完成
不适用
Magnesium sulfate in the treatment of acute asthmaISRCTN61336225Alexandria University60
已完成
不适用
Magnesium sulphate for the treatment of pre-eclampsia: a trial to evaluate the effects on women and babiesPregnancy and ChildbirthPre-eclampsiaISRCTN86938761Medical Research Council (MRC) (UK)10,141